Patients are searching for this trial right now

This page is already ranking on Google. Activate it to start receiving pre-qualified patient leads directly in your inbox.

14-day free trial · $44/mo after · Cancel anytime · Money-back guarantee

NCT06230185 · Personalis Inc.

CtDNA Based MRD Testing for NAC Monitoring in TNBC

(B-STRONGER-I)

What this study is about

A forward-looking, conducted at multiple hospitals, observational study to evaluate the correlation of Molecular Residual Disease (MRD) detection using circulating tumor DNA guided test to pathological full disappearance of disease signs (pCR) after neoadjuvant chemotherapy (NAC) in stage I-III triple negative breast cancer (TNBC).

View original scientific description

A prospective, multicenter, observational study to evaluate the correlation of Molecular Residual Disease (MRD) detection using circulating tumor DNA guided test to pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in stage I-III triple negative breast cancer (TNBC). Results from this study aim to improve MRD detection and disease outcomes for future patients.

Who can participate

This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.

Inclusion criteria

  • Have histologically documented TNBC (defined as ER expression ≤10% by IHC, PR expression≤10% by IHC and HER2 0 or 1+ by IHC or FISH ratio \<2 or HER2 gene copy number of \<6).
  • Early-stage breast cancer (stage I-III) and scheduled to undergo NAC treatment with curative intent.
  • Be informed of the investigational nature of the study and all pertinent aspects of the trial.
  • Have the ability to understand and the willingness to sign a written informed consent document in accordance with institutional and federal guidelines.
  • Be ≥ 18years of age.
  • Patient who are scheduled to start NAC.
  • Be willing to provide blood samples before and during treatment.
  • Have available biopsy tissue.

Exclusion criteria

  • Receiving concurrent anti-neoplastic therapy for another malignancy.
  • Stage IV disease.
  • Current or history of another primary cancer within 5 years of study entry, with the exception of basal or squamous cell skin cancer, or non-invasive malignancy.
  • History of allogeneic bone marrow or organ transplant.
  • Blood transfusion within two weeks before collection of blood for central ctDNA testing.
  • Started systemic therapy for their breast cancer.

Where

  • Tucson, Arizona
  • Aurora, Colorado
  • Washington D.C., District of Columbia
  • Miami Beach, Florida
  • St. Petersburg, Florida
  • Peoria, Illinois
  • New Orleans, Louisiana
  • Ypsilanti, Michigan
  • Omaha, Nebraska
  • Stony Brook, New York
  • Salem, Oregon
  • York, Pennsylvania

And 2 more locations — see the full list below.

Frequently asked questions

What is a clinical trial?

A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.

Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.

Will I be compensated?

Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.

Will I receive a placebo instead of treatment?

When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.

Can I leave a trial if I change my mind?

Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.

How long does a clinical trial last?

Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.

Data: ClinicalTrials.gov · synced Jan 7, 2025 · Source of record for eligibility and locations

📊
1 of 422 participants interested
0% interest

See if this study fits

A short prescreen based on this study's listed criteria. A coordinator confirms eligibility — this is not a medical assessment.

Preparing your pre-screening questions…

Study locations

Choose your preferred location, or select flexible during enrollment.

RECRUITING

Tucson

Arizona

Location available
RECRUITING

Aurora

Colorado

Location available
RECRUITING

Washington D.C.

District of Columbia

Location available
RECRUITING

Miami Beach

Florida

Location available
RECRUITING

St. Petersburg

Florida

Location available
RECRUITING

Peoria

Illinois

Location available
RECRUITING

New Orleans

Louisiana

Location available
RECRUITING

Ypsilanti

Michigan

Location available
RECRUITING

Omaha

Nebraska

Location available
View Omaha location page

And 5 more locations available.

Express your interest

Share your contact details and a study coordinator can follow up about screening.

Secure & Confidential

Your information is protected and will only be shared with the research team.

What participation can include

  • Study-related care provided by the research team
  • Close monitoring by medical professionals
  • Possible compensation for time and travel*
  • The option to withdraw at any time
  • Contributing to medical research that may help future patients

*Compensation varies by study. Confirm details with coordinator.

Typical next steps

  1. 1.Submit this form
  2. 2.Phone screening
  3. 3.In-person assessment if eligible
  4. 4.Begin participation

Find More Breast Cancer Trials by City

Browse all breast cancer clinical trials in these cities — not just this study.

Looking for TNBC - Triple-Negative Breast Cancer Treatment in Tucson?

Join others in Arizona exploring innovative treatment options through clinical research

TNBC - Triple-Negative Breast Cancer Treatment Options in Tucson, Arizona

If you're searching for TNBC - Triple-Negative Breast Cancer treatment in Tucson, participating in a clinical research study may provide access to innovative approaches under expert medical supervision. This study is actively recruiting participants in Tucson, Aurora, Washington D.C. and surrounding areas.

Clinical trials offer participants the opportunity to receive cutting-edge treatments while contributing to medical research that may help future patients with TNBC - Triple-Negative Breast Cancer. All study-related care is provided at no cost to participants.

Local Sites
3 locations in Arizona
Now Enrolling
Up to 422 participants
Quick Start
Screening available now

Why Consider a Clinical Trial for TNBC - Triple-Negative Breast Cancer?

Potential Benefits

  • Access to new treatment approaches before public availability
  • Close monitoring by experienced medical professionals
  • Study-related care provided at no cost
  • Contribute to medical research for TNBC - Triple-Negative Breast Cancer

What to Expect

  • Initial screening to determine eligibility
  • Regular check-ups and monitoring visits
  • Possible compensation for time and travel
  • You can withdraw at any time

Frequently Asked Questions About This TNBC - Triple-Negative Breast Cancer Study

Important Clinical Trial Information

This information is provided for educational purposes and does not constitute medical advice. Clinical trial participation involves potential risks and benefits. Eligibility requirements apply and will be assessed during the screening process.

Study identifier: NCT06230185. For complete study details, visit ClinicalTrials.gov. Always consult with your healthcare provider before making decisions about your medical care or participating in clinical research.